Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients
Status:
Recruiting
Trial end date:
2022-04-08
Target enrollment:
Participant gender:
Summary
Studies have shown that hip fractures have a significant perioperative blood loss.
Postoperative anaemia is associated with a higher morbidity and mortality.
Tranexamic acid is a safe and effective antifibrinolytic widely used to reduce blood loss in
other forms of orthopaedic surgery and in traumatized patients. However, evidence on the
effectiveness of TXA in lower extremity fracture care is more limited.
Hip fractures represent a common orthopedic injury in a fragile patient population that often
necessitates post-operative blood transfusion thereby putting the patient at additional risk
of complications.
The goal of this study is to assess if the use of tranexamic acid in patients with hip
fractures will result in a reduction in blood losses and blood transfusion rates.
Our hypothesis is that by providing intravenous TXA at the time of surgery will decrease the
amount of preoperative and intraoperative bleeding thereby leading to a decreased need for
postoperative transfusion.
This a double blinded, placebo controlled, therapeutic trial in which the patients will be
randomized to receive TXA or a placebo (saline solution). Treatment will be administered
pre-operatively as well as at the time of surgical incision. The primary outcome will be need
for blood transfusion. Secondary outcomes will include calculated perioperative blood loss,
length of stay, and rate of thromboembolic events, and 90 day mortality.